{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:11:28Z","timestamp":1788343888288,"version":"build-2803163510"},"reference-count":106,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2025,1,2]]},"DOI":"10.1080\/17425255.2024.2409931","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T07:57:28Z","timestamp":1727337448000},"page":"5-14","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A"],"prefix":"10.1080","volume":"21","author":[{"given":"Koji","family":"Yada","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.1.1.1"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/312337a0"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1987.tb13480.x"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)81537-5"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642524"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04879.x"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00025-0"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)69627-4"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1215"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00350a035"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03032.x"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656030"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655957"},{"key":"e_1_3_3_16_1","unstructured":"Japan Blood Products Organization. Prescribing information cross-eight MC. Internet. Japan: Japan Pharmaceutical Information Center JAPIC; Available from: https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00069205.pdf"},{"key":"e_1_3_3_17_1","unstructured":"Japan blood products organization (KM biologics). Prescribing information contact F. [Internet]. Japan: Japan Pharmaceutical Information Center JAPIC; Available from: http:\/\/www.kegg.jp\/medicus-bin\/japic_med?japic_code=00070193"},{"key":"e_1_3_3_18_1","unstructured":"Takeda. Prescribing information Advate. [Internet]. Japan: Japan Pharmaceutical Information Center JAPIC; [updated 2022 Jun;cited 2024 May 1]. Available from: https:\/\/www.kegg.jp\/medicus-bin\/japic_med?japic_code=00070193"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516437"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208024"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12952"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0191-4"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12816"},{"key":"e_1_3_3_24_1","unstructured":"CSL Behring. Prescribing information AFSTYLA. [Internet]. Japan: Japan Pharmaceutical Information Center JAPIC; Available from: https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00067175.pdf"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719858471"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0622-z"},{"key":"e_1_3_3_27_1","unstructured":"Takeda. Prescribing information Adynovate. Internet. United States; [updated 2023 Aug; cited 2024 May 1]. Available from: https:\/\/www.shirecontent.com\/PI\/PDFs\/ADYNOVATE_USA_ENG.pdf"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13561"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12220"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12161"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12506"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630897"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2265-6"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12911"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-713289"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02005.x"},{"key":"#cr-split#-e_1_3_3_38_1.1","unstructured":"Sanofi. FDA approves once-weekly ALTUVIIIO\u2122 a new class of factor VIII therapy for hemophilia a that offers significant bleed protection [media release]. [updated 2023 Feb 23"},{"key":"#cr-split#-e_1_3_3_38_1.2","unstructured":"cited 2024 May 1]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2023\/2023-02-23-21-00-00-2614759"},{"key":"#cr-split#-e_1_3_3_39_1.1","unstructured":"Swedish Orphan Biovitrum AB. FDA approves once-weekly efanesoctocog alfa a new class of high-sustained factor VIII therapy for haemophilia a [media release]. [updated 2023 Feb 23"},{"key":"#cr-split#-e_1_3_3_39_1.2","unstructured":"cited 2024 May 1]. Available from: https:\/\/www.sobi.com\/en\/press-releases\/fda-approves-once-weekly-efanesoctocog-alfa-new-class-high-sustained-factor-viii"},{"key":"#cr-split#-e_1_3_3_40_1.1","unstructured":"Swedish Orphan Biovitrum AB. Sobi strengthens haemophilia position with potential once-weekly haemophilia a treatment [media release]. [updated 2019 Sep 29"},{"key":"#cr-split#-e_1_3_3_40_1.2","unstructured":"cited 2024 May 1]. Available from: https:\/\/www.sobi.com\/en\/press-releases\/sobi-strengthens-haemophilia-position-potential-once-weekly-haemophilia-treatment"},{"key":"e_1_3_3_41_1","unstructured":"Amunix Inc. Biogen IDEC signs license agreement with amunix for XTENylated factor VIII [media release]. Available from: https:\/\/www.amunix.com\/newsroom\/press-releases\/2014\/042114\/"},{"key":"#cr-split#-e_1_3_3_42_1.1","unstructured":"Sanofi. Sanofi completes acquisition of bioverativ Inc. [media release]. [updated 2018 Mar 8"},{"key":"#cr-split#-e_1_3_3_42_1.2","unstructured":"cited 2024 May 1]. Available from: https:\/\/www.sanofi.com\/assets\/dotcom\/pressreleases\/2018\/2018-03-08-13-59-18-1418467-en.pdf"},{"key":"#cr-split#-e_1_3_3_43_1.1","unstructured":"Sanofi. Sanofi completes acquisition of Amunix [media release]. [updated 2022 Feb 8"},{"key":"#cr-split#-e_1_3_3_43_1.2","unstructured":"cited 2024 May 1]. Available from: https:\/\/www.sanofi.com\/assets\/dotcom\/pressreleases\/2022\/2022-02-08-13-51-22-2380928-en.pdf"},{"key":"#cr-split#-e_1_3_3_44_1.1","unstructured":"Sanofi. Once-weekly ALTUVIIIO\u00ae approved in Japan as a new class of factor VIII therapy for hemophilia a [media release]. [updated 2023 Sep 25"},{"key":"#cr-split#-e_1_3_3_44_1.2","unstructured":"cited 2024 May 1]. Available from:https:\/\/www.sanofi.com\/assets\/dotcom\/pressreleases\/2023\/2023-09-25-07-00-00-2748334-en.pdf"},{"key":"#cr-split#-e_1_3_3_45_1.1","unstructured":"Sanofi. Specialty care growth strong launch uptake of Beyfortus\u00ae and ALTUVIIIO\u00ae drive solid Q3 results [media release]. [updated 2023 Oct 27"},{"key":"#cr-split#-e_1_3_3_45_1.2","unstructured":"cited 2024 May 1]. Available from: https:\/\/www.sanofi.com\/assets\/dotcom\/pressreleases\/2023\/2023-10-27-05-31-00-2768149-en.pdf"},{"key":"#cr-split#-e_1_3_3_46_1.1","unstructured":"Sobi. European Commission grants Sobi\u00ae marketing authorisation for ALTUVOCT\u2122 for treatment of haemophilia a [media release]. [updated 2024 Jun 19"},{"key":"#cr-split#-e_1_3_3_46_1.2","unstructured":"cited 2024 Sep 15]. Available from: https:\/\/www.sobi.com\/sites\/sobi\/files\/pr\/202406183895-1.pdf"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009197"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001292"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1588"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.10.038"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15741"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209226"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312611"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006119"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002699"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100176"},{"key":"e_1_3_3_57_1","unstructured":"Sanofi. Prescribing information ALTUVIIIO. [internet]. Japan: Japan Pharmaceutical Information Center JAPIC; [updated 2024 Feb; cited 2024 May 1]. Available from: https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00071059.pdf"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148534"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108584"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1598058"},{"key":"e_1_3_3_61_1","unstructured":"Bioverative S. Long-term safety and efficacy of Efanesoctocog Alfa (BIVV001) in Previously treated patients with hemophilia a (xtend-ed). [Internet]. ClinicalTrials.gov; [cited 2024 May 1]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04644575"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14831"},{"key":"e_1_3_3_63_1","unstructured":"Sanofi. prescribing information Efanesoctocog alfa [Antihemophilic factor (recombinant) fc-VWF-XTEN fusion protein-ehtl]. Internet]. USA. [updated 2024 May; cited 2024 May 11]. Available from: https:\/\/products.sanofi.us\/altuviiio\/altuviiio.pdf"},{"key":"e_1_3_3_64_1","unstructured":"Sanofi. To assess the pharmacokinetics and safety and tolerability of Efanesoctocog Alfa (BIVV001) in adults with type 2N and 3 Von Willebrand disease (VWD). [[Internet]. ClinicalTrials.gov]. [cited 2024 May 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04770935"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057479"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-01-0030"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006684"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186535"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-023-03783-7"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03490-x"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14353"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-021-00760-4"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000253"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-155018"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18495"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.05129"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-369132"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12473"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12263"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12774"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(08)70003-3"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022756"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017780"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25874"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13064"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1419862"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2015.12.008"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02991"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2513-4"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001311"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02383.x"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09101.x"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801662"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2024.2409931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T14:27:52Z","timestamp":1735741672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2024.2409931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"alternative-id":["10.1080\/17425255.2024.2409931"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2024.2409931","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}